NanoTemper Technologies’ Post

Scientific publications require creation of hypotheses, experimental and assay development, careful analysis of results to ensure reproducibility, and trusted reagents. Our catalog of buffers are tested and trusted. See the number of publications that cite our products in the chart below and check out some recent peer reviewed publications cited with our products: https://lnkd.in/eZg5fXtR #custombuffers #customreagents #lifesciencebuffers #lifesciencereagents #diagnostics #biosimilar #bioprocessing #assaydevelopment 

In a recent publication, Merck researchers discovered the importance of incorporating flow into preclinical in vitro models. When comparing intestinal permeability of oral peptides, conventional 2D static cultures displayed a 4000-fold increase in permeability, whereas the microfluidic Gut-on-a-Chip model displayed a 20-fold increase, which is in line with ex vivo and in vivo preclinical models: https://hubs.ly/Q02H5VH90

Our latest article in dermal permeation modelling highlights the importance of determining the chemical composition of the follicular route before in vitro and in vivo testing to avoid misleading results. Thanks Tao Chen and Guoping Lian for such a fruitful collaboration over the years! Check the article here:

Affinity Selection Mass Spectrometry (ASMS) is a powerful technique in drug discovery, efficiently identifying small molecules for protein-protein interactions (PPIs) and other challenging targets, such as membrane proteins and RNA. Drug discovery experts acknowledged at the recent DDC conference their utilization of services from WuXi AppTec, underlining the practical effectiveness of ASMS in discovering potential hits on those challenging targets. WuXi AppTec’s ASMS platform has demonstrated high proficiency in this field, as shown by our case studies involving successful screening of membrane proteins and identification of molecular glues. Click 👇 to explore our ASMS platform and access the mini posters from our showcases. #ASMS #MembraneProtein #MolecularGlue #PPI #TPD #CIP #RNA #DDC #DrugDiscovery https://lnkd.in/g44Nh6E2

Achieving Rapid #LC-MS Analyses Using #Avantor® #ACE® #HTP-MS #Columns Achieving fast LC analyses is essential in high sample throughput laboratories, such as clinical, drug discovery and environmental labs. Over the last two decades, #UHPLC has enabled many labs to dramatically increase sample throughput, through use of shorter columns packed with sub-2 micron particles. However, at the same time, the performance of modern mass spectrometers has continued to evolve. Improved sensitivity and ultra-fast data acquisition capabilities, provide opportunities to further reduce analytical run times, using specially designed, high throughput columns. This #webinar begins by discussing the concepts of how to develop high throughput LC-MS methods, before introducing the Avantor® ACE® HTP-MS column. The use of this column format to develop ultra-fast LC-MS analyses will be discussed, along with several key applications that demonstrate the advantages that can be realised. Finally, some of the challenges associated with rapid analysis will be discussed, including aspects of sample preparation and the impact the matrix can have on the detector. For more information, please contact us at webinar@avantorsciences.com #REGISTER NOW! https://lnkd.in/dpZ-yFhs

Final open access version of our research paper on Lp(a) is now online👇 https://lnkd.in/dey95Wz2 In this real-world study involving 185,493 individuals, we observed that transitioning from one Lp(a) immunoassay to another affected the proportion of individuals with Lp(a) levels above clinical thresholds. While the majority of individuals had low levels (<30 mg/dL) of Lp(a), the Roche assay detected 20% more individuals with Lp(a)>50 mg/dL, 40% more individuals with Lp(a) >100 mg/dL and 80% more individuals with Lp(a)>180 mg/dL than the currently used Siemens assay. TAKE-HOME MESSAGE 👉Metrological traceability is needed: the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) works on mass spectrometry (MS) standard. 👉Clinicians may consider re-measuring Lp(a) in individuals close to relevant thresholds due to changes in methodology over time. 👉Risk assessments should be reported along an ordinal scale, not only dividing in low or high Lp(a).

[Live webinar alert!] Inside the technical note. Chapter 3 Join us for the final 'Inside the technical note' live webinar. where we unveil the latest technical notes and explore the secrets behind their discoveries. Technical notes covered: - Development of an acetylcholinesterase biochemical assay using the SCIEX Echo® MS system -Enhanced drug metabolite identification using collision-induced dissociation (CID) and electron-activated dissociation (EAD) -A sensitive method for the quantitation of bimatoprost in human plasma Register today! https://bit.ly/3uCFHk7 #SCIEX #DrugDevelopment

⭐Blog Highlight⭐     We recently published a blog post ("The DELephant in the Room") spotlighting five important drawbacks to consider before pursuing traditional DEL-based screening approaches for drug discovery. Here’s a preview:     🚫 Downside #2: Test compounds must be tagged.     💬 "Relative to an untagged small-molecule ligand, generally 0.1 to 1 kDa, a DEL tag is overwhelmingly massive – its addition can increase a ligand’s size by more than a hundredfold!”      💬 "Affinity Selection Mass Spectrometry, which screens untagged ligand libraries, avoids these obstacles.”     Read the full post at: https://lnkd.in/dFZmjnTr  Plus, stay tuned for more DEL Downsides in the coming weeks!     #DrugDiscovery #HighThroughputScreening #DELScreening #AffinitySelectionMassSpectrometry 

Optimize your lead compound with our tools! Enhance pharmacological, physicochemical, and ADME properties through preclinical and clinical trials for smoother sailing. Learn more here: https://bit.ly/4bFc2If #DrugDiscovery #HitOptimization #ReliableResults